65,437 trials
Neural Tube Defects · Anemia · Leukemia, Myeloid
Primary: Full Donor Chimerism (FDC) — 6 Participants
Multiple Myeloma · Autologous Stem Cell Transplant
Primary: Progression Free Survival (PFS) — 21.3; 26.5 months — p=0.002
Post Operative Pain
Primary: Pain Intensity Score of Oxymorphone IR Oral Liquid in Pediatric Subjects by Age Group and Time Points in Single Dose Phase — 4.5; 3.4; 2.4; 3.5 score on a scale
Prostate Cancer
Primary: Percentage of Participants With Reduction in Acute Per-prostatic Rectal Ulcer Events Events From 90%+ to <70% (Particularly in the Anterior Rectum) — 13.6 percentage of…
Alopecia Areata
Primary: Change in SALT Score — 65.8; 24.8; 7.3 score on a scale
Hepatitis C
Primary: Treatment Efficacy — 88; 75 % of participants
Traumatic Brain Injury
Primary: Trail Making Test Part B — 52.1; 45.3; 52.9; 50.8 T-score
Multiple Sclerosis
Primary: Symbol Digit Modalities Test — 41.18; 35.06; 45.05; 38.63 score on a scale
Congenital Heart Disease
Primary: Total Units of Intraoperative Allogenic Donor Transfusions (ADT) Administered During Procedure Through ICU Arrival. — 5; 4 ADT units
Asthma
Primary: GPA — 2.75; 2.61; 3.25; 2.50 GPA(unweighted)
Pain, Postoperative
Primary: Total Narcotic Consumption During Hospital Stay — 90.79; 90.30 Oral Morphine Equivalents per day (OME) — p=0.97
Pain, Postoperative
Primary: Patient Reported Pain — 4.12; 4.37 score on a scale
Obesity
Primary: Percent Change in Baseline Weight — -6.1; -11.5; -11.8 percent change
Efficiency of Surgical Incision Closure · Post-operative Scar
Primary: Operative Time to Closure of Final Skin Layer — 58.38; 444.76 seconds
Nicotine Dependence
Primary: Time-to-lapse — 51.97; 56.44 Minutes